Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Peresolimab - Eli Lilly and Company

Next Previous
Search
Drug Profile

Peresolimab - Eli Lilly and Company

Alternative Names: LY-3462817

Latest Information Update: 04 Feb 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Eli Lilly and Company
  • Class Antipsoriatics; Antirheumatics; Monoclonal antibodies
  • Mechanism of Action Programmed cell death 1 receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Rheumatoid arthritis
  • No development reported Plaque psoriasis

Most Recent Events

  • 17 Jan 2025 Eli Lilly and Company completes the phase II RESOLUTION-1 trial in Rheumatoid arthritis (Treatment-experienced) in Spain, Puerto Rico, Poland, Mexico, Japan, Italy, Hungary, Greece, China, Canada, Argentina (SC) (NCT05516758)
  • 12 Jun 2024 Pharmacodynamics data from phase II clinical trials in Rheumatoid arthritis presented at the 25th Annual Congress of the European League Against Rheumatism (EULAR-2024)
  • 11 Jan 2024 Eli Lily and Company completes a phase I safety and pharmacokinetics trial (In volunteers) in USA (SC) (NCT05959109)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top